Drug Profile
BMS 986148
Alternative Names: BMS-986148; Mesothelin-ADC - BMSLatest Information Update: 22 Nov 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Peptides
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Gastric cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
- No development reported Solid tumours
Most Recent Events
- 16 Nov 2021 Bristol-Myers Squibb terminates phase I/IIa trial in Gastric cancer, Ovarian cancer, Non small cell lung cancer, Mesothelioma, Pancreatic cancer (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in Australia, Belgium, Italy, Canada, Netherlands, United Kingdom and USA (EudraCT2014-002485-70) (NCT02341625)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Japan (IV, Injection)
- 28 Oct 2019 Preliminary adverse events, efficacy and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 (AACR-NCI-EORTC-2019)